Tetanus Toxoid Vaccine Market Research Report- Global Forecast till 2023

Tetanus Toxoid Vaccine Market Research Report- Global Forecast till 2023

ID: MRFR/HC/2707-HCRR | October, 2018 | Region: Global | 90 pages | Half-Cooked Research Reports

Tetanus toxoid vaccine market information: by types (monovalent Tetanus Toxoid (TT), Diphtheria, Tetanus, and Pertussis (DTaP), Diphtheria and Tetanus (DT), tetanus, diphtheria, and pertussis (Tdap), others) by forms (quadrivalent, pentavalent, hexavalent) by end users (hospitals and clinics, government organizations, research, others) - Global Forecast till 2023  



Market Synopsis of global Tetanus toxoid vaccine market:


Market scenario:


Tetanus is an infectious disease caused by Clostridium tetani characterized by muscle spasms. The spasms may be very severe and even cause bone fractures. Other symptoms include fever, sweating, headache, trouble swallowing, hypertension etc. About 10% of those infected, die while a large number become incapacitated due to bone fractures. Tetanus toxoid vaccine is an inactive vaccine used to prevent tetanus by developing immunity against the pathogen causing tetanus. The general dosage recommendation is five doses during childhood, with a sixth given during adolescence with additional doses every 10 years. The tetanus vaccine was initially developed in 1924 and has resulted in a 95% decrease in the rate of tetanus in the US and is on the World Health Organization's List of Essential Medicines. The vaccine also is considered very safe even during pregnancy and for those with HIV.


The market restraints of the tetanus toxoid vaccine are redness and pain at the site of injection, fever, and fatigue and muscles pains. Severe allergic reactions are the most serious side effects of the Tetanus toxoid vaccine which occur in less than one in 100,000 people. The market for tetanus toxoid vaccine is bipolar with contractual market having a sizable number of share as compared to the private market. The other market constraints include falling profitability of vaccine manufacturing, huge reduction of tetanus in the developed world which effectively eliminates the need for further vaccination due to herd immunity, side effects associated with vaccines, variability of efficacy of tetanus toxoid vaccine etc.


The low profitability in vaccine manufacturing has reduced incentives for developing vaccines for diseases of the developing world such as tuberculosis and malaria.


Considering all these factors, the market for Tetanus toxoid vaccine is expected to reach $ 5.5 billion by the end of 2023, this market is projected to growing at a CAGR of ~ 5.3 % during 2017-2023.


 


Sources: Mayo Clinic, MRFR Analysis.


Intended Audience



  • Global Tetanus toxoid vaccine manufacturers & suppliers

  • Research and development (R&D) companies

  • Hospitals and clinics

  • Academic institutes and universities



Figure 1         Global Tetanus toxoid vaccine market by End Users, 2016 (% Market Share)

 


Segments:


The global tetanus toxoid vaccine market is segmented on the basis of types, forms and end users. Based on types, the market has been segmented as monovalent tetanus toxoid (TT), diphtheria, tetanus, and pertussis (DTaP), diphtheria and tetanus (DT), tetanus, diphtheria, and pertussis (Tdap) and others. Based on the forms, the market has been segmented as quadrivalent, pentavalent, and hexavalent. Based on the end users, the market has been segmented as biotech and hospitals and clinics, government organizations, research and others.


Regional analysis


US accounts for the maximum market share due to greater use of medications and greater expenditure on healthcare. The faster market uptake of new technology and devices in the US is also an important driver of the market for global Tetanus toxoid vaccine. Europe is the second largest market due to large disposable income and rising awareness. Asia Pacific region is expected to have the most future potential and it is estimated to be led by China and India. The Middle East & Africa market is led by the gulf nations particularly Saudi Arabia and UAE. The regions of Africa are expected to witness a moderate growth due to poor economic and political conditions and poor healthcare penetration.


Key players of Global Tetanus toxoid vaccine market:


Key players profiled in the report are GlaxoSmithKline Plc., Merck & Co. Inc., Pfizer, Inc., Sanofi Pasteur, Inc., AstraZeneca Plc., Bharat Biotech, Shenzhen Kangtai Biological Products, Valeant Pharmaceuticals, Emergent Biosolutions Inc., Astellas Pharma Inc., Panacea Biotec and others.

The report for
Global Tetanus toxoid vaccine market by Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.

1. Introduction

1.1 Definition

1.2 scope of study

1.2.1 Research Objective

1.2.2 Assumptions & Limitations

1.2.2.1 Assumptions

1.2.2.2 Limitations

1.3 Market Structure:

2. Research Methodology

2.1 Research Process:

2.2 Primary Research

2.3 Secondary Research:

3. Market dynamics

3.1 Drivers

3.2 Restraints

3.3 Opportunities

3.4 Macroeconomic Indicators

4. Market factor analysis

4.1 Porters Five Forces Model

4.2 Bargaining Power Of Suppliers

4.3 Bargaining Power Of Buyers

4.4 Threat Of New Entrants

4.5 Threat Of Substitutes

4.6 Intensity Of Rivalry

5. Global Tetanus Toxoid Vaccine Market, by Types

5.1 Monovalent Tetanus Toxoid (TT)

5.2 Diphtheria, Tetanus, And Pertussis (Dtap)

5.3 Diphtheria And Tetanus (Dt)

5.4 Tetanus, Diphtheria, And Pertussis (Tdap)

5.5 Others

6. Global Tetanus Toxoid Vaccine Market, By Forms

6.1 Quadrivalent

6.2 Pentavalent

6.3 Hexavalent

7. Global Tetanus Toxoid Vaccine Market, By End Users

7.1 Hospitals And Clinics

7.2 Government Organizations

7.3 Research

7.4 Others

8. Global Tetanus Toxoid Vaccine Market, By Region

8.1 North America

8.1.1 Introduction

8.2 Europe

8.2.1 Introduction

8.3 Asia-Pacific

8.3.1 Introduction

8.4 Middle East & Africa

8.4.1 Introduction

9. Competitive landscape

9.1 Major Strategies Adopted By Market Players

9.1.1 Strategic Partnership

9.1.2 Merger & Acquisition

10. Company profile

10.1 GlaxoSmithKline Plc.

10.1.1 Overview

10.1.2 Product Overview

10.1.3 Financials

10.1.4 Key Developments

10.2 Merck & Co. Inc.

10.2.1 Overview

10.2.2 Product Overview

10.2.3 Financials

10.2.4 Key Developments

10.3 Pfizer, Inc.

10.3.1 Overview

10.3.2 Product Overview

10.3.3 Financials

10.3.4 Key Development

10.4 Sanofi Pasteur, Inc.

10.4.1 Overview

10.4.2 Product Overview

10.4.3 Financials

10.4.4 Key Developments

10.5 AstraZeneca Plc.

10.5.1 Overview

10.5.2 Product Overview

10.5.3 Financials

10.5.4 Key Developments

10.6 Bharat Biotech

10.6.1 Overview

10.6.2 Product Overview

10.6.3 Financials

10.6.4 Key Developments

10.7 Sanofi S.A.

10.7.1 Overview

10.7.2 Product Overview

10.7.3 Financials

10.7.4 Key Developments

10.8 Shenzhen Kangtai Biological Products

10.8.1 Overview

10.8.2 Product Overview

10.8.3 Financials

10.8.4 Key Developments

10.9 Valeant Pharmaceuticals

10.9.1 Overview

10.9.2 Product Overview

10.9.3 Financials

10.9.4 Key Developments

10.10 Emergent Biosolutions Inc.,

10.10.1 Overview

10.10.2 Product Overview

10.10.3 Financials

10.10.4 Key Developments

10.11 Astellas Pharma Inc.

10.11.1 Overview

10.11.2 Product Overview

10.11.3 Financials

10.11.4 Key Developments

10.12 Panacea Biotec.

10.12.1 Overview

10.12.2 Product Overview

10.12.3 Financials

10.12.4 Key Developments

10.13 Other

11. Conclusion

11.1 Key Findings

11.1.1 From Ceo’s Viewpoint

11.1.2 Unmet Needs Of The Market

11.2 Key Companies To Watch

11.3 Prediction Of Tetanus Toxoid Vaccine Treatment Industry

12. Appendix